checkAd

    DGAP-News  178  0 Kommentare Virpax(R) Pharmaceuticals Inc.: Virpax Pharmaceuticals Announces Newly Issued Patent for Probudur(TM) - Seite 2

    Forward-Looking Statement

    This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's planned clinical trials, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

    These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on the Company's operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

    Seite 2 von 3




    EQS Group AG
    0 Follower
    Autor folgen
    Verfasst von EQS Group AG
    DGAP-News Virpax(R) Pharmaceuticals Inc.: Virpax Pharmaceuticals Announces Newly Issued Patent for Probudur(TM) - Seite 2 DGAP-News: Virpax(R) Pharmaceuticals Inc. / Key word(s): Miscellaneous Virpax(R) Pharmaceuticals Inc.: Virpax Pharmaceuticals Announces Newly Issued Patent for Probudur(TM) 02.03.2021 / 14:00 The issuer is solely responsible for the content of …